A new peptide compound currently under evaluation (retatrutide) allows for an average body weight reduction of 28% according to recent clinical studies.

noli's read

This statement is entirely accurate and is based on very solid scientific data. The phase 3 trial named TRIUMPH-1, a large-scale randomized controlled trial (RCT) conducted by the laboratory Eli Lilly and unveiled in May 2026, shows that participants using this compound at its maximum dose reduced their weight by 28.3% on average after 80 weeks. This active ingredient works by mimicking three natural body messengers that regulate satiety, energy expenditure, and fat burning. However, it must be specified that this impressive figure is an average obtained with the highest dose and that results vary depending on individual profiles. Furthermore, such a physical transformation requires particular attention to preserve muscle vitality and avoid transient digestive discomfort during the adjustment phase. Finally, this product remains under scientific validation and is not yet available for daily wellness purposes.

the sources

1. 1Wilding JPH et al. (STEP 1) 2021
2. 2Jastreboff AM et al. (SURMOUNT-1) 2022
3. 3Jastreboff AM et al. 2023
4. 4Wilding JPH et al. (STEP 1 extension) 2022